117 related articles for article (PubMed ID: 6235758)
1. The role of fibrinolysis in the therapy of peripheral vascular disease.
Ambrus CM; Ambrus JL; Gastpar H; Sharma SD; Suh OW; Moore RH; Williams P
Angiology; 1984 Jul; 35(7):436-42. PubMed ID: 6235758
[TBL] [Abstract][Full Text] [Related]
2. Studies of the clinical pharmacology and therapeutic efficacy of pentoxifylline in peripheral obstructive arterial disease.
Di Perri T; Carandente O; Vittoria A; Guerrini M; Messa GL
Angiology; 1984 Jul; 35(7):427-35. PubMed ID: 6540539
[TBL] [Abstract][Full Text] [Related]
3. Studies on platelet aggregation inhibitors in vivo. X. Relationship to thrombolysis.
Ambrus JL; Ambrus CM; Sharma SD; Suh OW; Gastpar H
J Med; 1982; 13(5-6):365-71. PubMed ID: 6221055
[TBL] [Abstract][Full Text] [Related]
4. [Fibrinolytic therapy of peripheral arterial occlusive disease].
Sailer S; Pilger E
Wien Med Wochenschr; 1985 Aug; 135(15-16):393-9. PubMed ID: 2932859
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of thrombolytic therapy by enzyme combinations and with aspirin or pentoxifylline.
Ambrus JL; Ambrus CM; Stadler S; Toumbis C; Markus G
J Med; 1994; 25(3-4):145-61. PubMed ID: 7996060
[TBL] [Abstract][Full Text] [Related]
6. Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis.
Terres W; Beythien C; Kupper W; Bleifeld W
Circulation; 1989 Jun; 79(6):1309-14. PubMed ID: 2720929
[TBL] [Abstract][Full Text] [Related]
7. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training.
Scheffler P; de la Hamette D; Gross J; Mueller H; Schieffer H
Circulation; 1994 Aug; 90(2):818-22. PubMed ID: 8044953
[TBL] [Abstract][Full Text] [Related]
8. [Position and developmental trends in fibrinolytic therapy].
Markwardt F
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):6-17. PubMed ID: 2427416
[TBL] [Abstract][Full Text] [Related]
9. Fatal ischaemic brain oedema after unsuccessful thrombolysis.
Overgaard K; Pedersen H; Knudsen JB; Boysen G
Neurol Res; 1990 Jun; 12(2):81-2. PubMed ID: 1974705
[No Abstract] [Full Text] [Related]
10. PGE1 accelerates thrombolysis by tissue plasminogen activator.
Vaughan DE; Plavin SR; Schafer AI; Loscalzo J
Blood; 1989 Apr; 73(5):1213-7. PubMed ID: 2495035
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of urokinase and tissue-type plasminogen activator in transcatheter arterial fibrinolysis].
Vignali C; Cioni R; Mascalchi M; Russo R; Palla A; Lencioni R; Napoli V; Bartolozzi C
Radiol Med; 1994; 88(1-2):93-9. PubMed ID: 8066262
[TBL] [Abstract][Full Text] [Related]
12. [Biological profile of the 1st 4 hours of a thrombolytic treatment combining urokinase with lysyl-plasminogen].
Roncato M; Vitoux JF; Pernes JM; Aiach M; Fiessinger JN; Gaux JC; Housset E; Leclerc M
Ann Biol Clin (Paris); 1985; 43(6):851-5. PubMed ID: 3832977
[TBL] [Abstract][Full Text] [Related]
13. [Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].
Weiss T
Vasa; 2003 Nov; 32(4):187-92. PubMed ID: 14694766
[TBL] [Abstract][Full Text] [Related]
14. Pentoxifylline treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis.
Poggesi L; Scarti L; Boddi M; Masotti G; Serneri GG
Angiology; 1985 Sep; 36(9):628-37. PubMed ID: 3901827
[TBL] [Abstract][Full Text] [Related]
15. Intraarterial fibrinolysis: in vitro and prospective clinical evaluation of three thrombolytic agents.
Pilger E; Lammer J; Bertuch H; Steiner H
Radiology; 1986 Dec; 161(3):597-9. PubMed ID: 3786705
[TBL] [Abstract][Full Text] [Related]
16. Red cell flexibility and platelet aggregation in patients with chronic obstructive vascular disease (COAD) and study of therapeutic approaches.
Ambrus JL; Ambrus CM; Taheri SA; Gastpar H; Reddington MM; Taheri P; Kahn EA; Schattman GL; Dean LS; Moore RH
Angiology; 1984 Jul; 35(7):418-26. PubMed ID: 6540538
[TBL] [Abstract][Full Text] [Related]
17. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
[TBL] [Abstract][Full Text] [Related]
18. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
Veremeenko KN; Kizim AI
Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
[TBL] [Abstract][Full Text] [Related]
19. Hemostatic and fibrinolytic effects of systemic prostaglandin E1 therapy in patients with peripheral arterial disease.
Kuss M; Heidrich H; Koettgen E
Vasa; 2003 Aug; 32(3):145-8. PubMed ID: 14524034
[TBL] [Abstract][Full Text] [Related]
20. [Laboratory control of fibrinolytic therapy].
Vinazzer H
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):30-7. PubMed ID: 2427412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
